Suppr超能文献

IFIT1+中性粒细胞是低黏附性癌(PCC)免疫抑制特征的致病因素。

IFIT1 + neutrophil is a causative factor of immunosuppressive features of poorly cohesive carcinoma (PCC).

机构信息

Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, 210029, Jiangsu, China.

No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.

出版信息

J Transl Med. 2024 Jun 19;22(1):580. doi: 10.1186/s12967-024-05389-z.

Abstract

The importance of the immune microenvironment in poorly cohesive carcinoma (PCC) has been highlighted due to its limited response rate to conventional therapy and emerging treatment resistance. A combination of clinical cohorts, bioinformatics analyses, and functional/molecular experiments revealed that high infiltration of Interferon Induced Protein with Tetratricopeptide Repeats 1 (IFIT1) + tumor-associated neutrophils (TANs) is a distinguishing feature of PCC patients. Upregulation of IFIT1 + TANs promote migration and invasion of gastric cancer (GC) cell lines (MKN45 and MKN74) and stimulates the growth of cell-derived xenograft models. Besides, by promoting macrophage secreted phosphoprotein 1 (SPP1) expression and facilitating cancer-associated fibroblast and endothelial cell recruitment and activation through TANs, IFIT1 promotes a mesenchymal phenotype, which is associated with a poor prognosis. Importantly, compared to non-PCC (NPCC), PCC tumors is more immunosuppressive. Mechanistically, IFIT1 can be stimulated by IFN-γ and contributes to the expression of Programmed Cell Death 1 Ligand (PDL1) in TANs. We demonstrated in mouse models that IFIT1 + PDL1 + TANs can induce acquired resistance to anti-PD-1 immunotherapy, which may be responsible for the difficulty of PCC patients to benefit from immunotherapy. This work highlights the role of IFIT1 + TANs in mediating the remodeling of the tumor immune microenvironment and immunotherapeutic resistance and introduces IFIT1 + TANs as a promising target for precision therapy of PCC.

摘要

免疫微环境在黏附性差的癌(PCC)中的重要性已得到凸显,因为其对常规治疗的反应率有限,且治疗耐药性不断出现。临床队列、生物信息学分析和功能/分子实验的综合结果表明,干扰素诱导蛋白具有四肽重复序列 1(IFIT1)+肿瘤相关中性粒细胞(TAN)的高浸润是 PCC 患者的一个显著特征。IFIT1+TAN 的上调可促进胃癌(GC)细胞系(MKN45 和 MKN74)的迁移和侵袭,并刺激细胞衍生的异种移植模型的生长。此外,IFIT1 通过促进巨噬细胞分泌的磷蛋白 1(SPP1)的表达,并通过 TAN 促进癌症相关成纤维细胞和内皮细胞的募集和激活,促进间充质表型,这与预后不良相关。重要的是,与非 PCC(NPCC)相比,PCC 肿瘤的免疫抑制作用更强。在机制上,IFIT1 可被 IFN-γ 刺激,并有助于 TAN 中程序性细胞死亡配体 1(PDL1)的表达。我们在小鼠模型中证明,IFIT1+PDL1+TAN 可诱导对抗 PD-1 免疫治疗的获得性耐药,这可能是 PCC 患者难以从免疫治疗中获益的原因。这项工作强调了 IFIT1+TAN 在介导肿瘤免疫微环境重塑和免疫治疗耐药中的作用,并提出 IFIT1+TAN 作为 PCC 精准治疗有前途的靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26c1/11188200/4d0027aed4e8/12967_2024_5389_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验